Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822496 | 0.93 | HRH3 (0.56) | HRH3HPGDKDM2BNAMPTKMT2A | |
| SCHEMBL1787705 | 0.88 | HRH3 (0.61) | HRH3KDM2B | |
| SCHEMBL1788748 | 0.82 | SMN1; SMN2 (0.56) | HRH3SMN1; SMN2KMT2A | |
| SCHEMBL1790897 | 0.82 | HRH3 (0.76) | HRH3KDM2BL3MBTL3L3MBTL1 | |
| SCHEMBL1788776 | 0.81 | HRH3 (0.54) | HRH3KDM2B | |
| SCHEMBL1789796 | 0.81 | HRH3 (0.54) | HRH3HPGDKDM2BNAMPTKMT2A | |
| SCHEMBL1791299 | 0.81 | SMYD3 (0.59) | HRH3HPGDSMN1; SMN2KDM2B | |
| SCHEMBL1789719 | 0.81 | HRH3 (0.53) | HRH3HPGDKDM2BNAMPTKMT2A | |
| SCHEMBL12608452 | 0.80 | MAPT (0.53) | HRH3KDM2BL3MBTL1 | |
| SCHEMBL1787748 | 0.80 | SMYD3 (0.57) | HRH3HPGDSMN1; SMN2KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007735-B1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | HRH3 16/4885HPGD 118/4885DRD2 2461/4885 |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | HRH3 2/4885HPGD 191/4885DRD2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.